Grant L, Seiding Larsen L, Burrows K, et al. Development of a conceptual model of Chronic Hand Eczema (CHE) based on qualitative interviews with patients and expert dermatologists. Adv Ther. 2020;37(2):692–706.

Article  PubMed  PubMed Central  Google Scholar 

Dibenedetti D, Baranowski E, Zelt S, Reynolds M, Sherrill B. Assessing United States patient and dermatologist experiences with severe Chronic Hand Eczema. J Clin Aesthet Dermatol. 2015;8(11):19–27.

PubMed  PubMed Central  Google Scholar 

Zalewski A, Krajewski PK, Szepietowski JC. Prevalence and characteristics of itch and pain in patients suffering from Chronic Hand Eczema. J Clin Med. 2023;12(13):4198.

Article  PubMed  PubMed Central  Google Scholar 

Moberg C, Alderling M, Meding B. Hand eczema and quality of life: a population-based study. Br J Dermatol. 2009;161(2):397–403.

Article  CAS  PubMed  Google Scholar 

Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of Chronic Hand Eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840.

Article  PubMed  Google Scholar 

Egeberg A, Schlapbach C, Haugaard JH, et al. Adverse events from topical corticosteroid use in Chronic Hand Eczema—findings from the Danish Skin Cohort. JAAD Int. 2024;14:77–83.

Article  PubMed  Google Scholar 

Sloot MM, Loman L, Romeijn GLE, Rosenberg FM, Arents BWM, Schuttelaar MLA. Patients’ perspectives on quality of care for Chronic Hand Eczema: a qualitative study. Contact Dermat. 2022;86(3):204–12.

Article  Google Scholar 

Ronsch H, Schiffers F, Ofenloch R, et al. Chronic Hand Eczema in Europe: patient experiences and perspectives (CHEPEP) in qualitative interviews. J Eur Acad Dermatol Venereol. 2023;37(7):1396–405.

Article  CAS  PubMed  Google Scholar 

Weidinger S, Novak N. Hand eczema. Lancet. 2024;404(10470):2476–86.

Article  CAS  PubMed  Google Scholar 

Lerbaek A, Kyvik KO, Ravn H, Menne T, Agner T. Clinical characteristics and consequences of hand eczema—an 8-year follow-up study of a population-based twin cohort. Contact Dermat. 2008;58(4):210–6.

Article  Google Scholar 

Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermat. 2022;86(5):357–78.

Article  Google Scholar 

Bauer A, Thyssen JP, Buhl T, et al. Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of Chronic Hand Eczema: results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial. Contact Dermat. 2023;89(1):46–53.

Article  CAS  Google Scholar 

Silverberg JI, Agner T, Baranowski K, et al. Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity. Arch Dermatol Res. 2024;316(4):110.

Article  PubMed  PubMed Central  Google Scholar 

Molin S, Larsen LS, Joensson P, et al. Development and psychometric validation of a patient-reported outcome measure to assess the signs and symptoms of Chronic Hand Eczema: the Hand Eczema Symptom Diary (HESD). Dermatol Ther (Heidelb). 2024;14(3):643–69.

Article  PubMed  Google Scholar 

Kluzek S, Dean B, Wartolowska KA. Patient-reported outcome measures (PROMs) as proof of treatment efficacy. BMJ Evid Based Med. 2022;27(3):153–5.

Article  PubMed  Google Scholar 

Almeida D, Umuhire D, Gonzalez-Quevedo R, Antonio A, Burgos JG, Verpillat P, et al. Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU. Front Med (Lausanne). 2024;11:1408636.

Article  PubMed  Google Scholar 

US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.

Article  Google Scholar 

Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41–51.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Delgocitinib (Anzupgo®): Summary of Product Characteristics. European Medicines Agency (EMA); 2024. https://www.ema.europa.eu/en/documents/product-information/anzupgo-epar-product-information_en.pdf. Accessed 15 Aug 2025.

ANZUPGO® (delgocitinib) cream [prescribing information]. 2025; Madison, New Jersey: LEO Pharma Inc. [updated 08/2025].

ANZUPGO®. Product Monograph. LEO Pharma Inc.; 2024b. Toronto, Ontario: LEO Pharma Inc. [updated 08/2025]. https://pdf.hres.ca/dpd_pm/00081515.PDF. Accessed 15 Aug 2025.

Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461–73.

Article  CAS  PubMed  Google Scholar 

Oosterhaven JAF, Schuttelaar MLA. Responsiveness and interpretability of the Hand Eczema Severity Index. Br J Dermatol. 2020;182(4):932–9.

Article  CAS  PubMed  Google Scholar 

Armstrong A, Hahn-Pedersen J, Bartlett C, Glanville J, Thyssen JP. Economic burden of Chronic Hand Eczema: a review. Am J Clin Dermatol. 2022;23(3):287–300.

Article  PubMed  PubMed Central  Google Scholar 

Voorberg AN, Kamphuis E, Christoffers WA, Schuttelaar MLA. Efficacy and safety of dupilumab in patients with severe Chronic Hand Eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. Br J Dermatol. 2023;189(4):400–9.

Article  CAS  PubMed  Google Scholar 

Passlov HM, Ponten A, Bjork J, et al. Hand strength and dexterity in individuals with hand eczema. J Eur Acad Dermatol Venereol. 2020;34(12):2856–62.

Article  CAS  PubMed  Google Scholar 

Leshem YA, Chalmers JR, Apfelbacher C, et al. Measuring atopic eczema control and itch intensity in clinical practice: a consensus statement from the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) initiative. JAMA Dermatol. 2022;158(12):1429–35.

Article  PubMed  Google Scholar 

Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and Chronic Hand Eczema in adults. Patient. 2019;12(5):445–59.

Article  PubMed  PubMed Central  Google Scholar 

Silverberg JI, DeLozier A, Sun L, et al. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19(1):247.

Article  PubMed  PubMed Central  Google Scholar 

Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nugent SM, Lovejoy TI, Shull S, Dobscha SK, Morasco BJ. Associations of pain numeric rating scale scores collected during usual care with research administered patient reported pain outcomes. Pain Med. 2021;22(10):2235–41.

Article  PubMed  PubMed Central  Google Scholar 

Brands MJ, Loman L, Schuttelaar MLA. Exposure and work-related factors in subjects with hand eczema: data from a cross-sectional questionnaire within the Lifelines Cohort Study. Contact Dermat. 2022;86(6):493–506.

Article  Google Scholar 

Gooderham M, Molin S, Bissonnette R, et al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol. 2025;93(1):95–103.

Article  CAS  PubMed  Google Scholar 

Gimenez-Arnau AM, Pinter A, Sondermann W, et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe Chronic Hand Eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial. Lancet. 2025;405(10490):1676–88.

Article  CAS